Friday 14 Feb 2020 @ 12:15
National Institute for Health and Clinical Excellence (NICE)
Wireless device recommended for treating people with overactive bladder
Axonics SNS has potential to save the NHS around £6,200 per patient if the device lasts more than six years
People with an overactive bladder could have a rechargeable wireless device fitted to ease their condition, NICE has said in new draft guidance.
Inserted under the skin in the upper buttock, the Axonics sacral neuromodulation (SNM) stimulates the sacral nerve with an electric current via an electrode (thin wire). The electrode is attached to an implantable pulse generator which stimulates the nerves associated with bladder function. The aim of the stimulation is to make the bladder work in a more controllable way; a bit like a pacemaker for the heart.
A handheld remote control operated by the patient activates the stimulator, adjusts the stimulation amplitude, and checks the battery status. A wireless charger, attached to the implanted stimulator over the skin, is used to charge the stimulator. It is claimed by the company that the battery needs a recharge every 1-2 weeks for 30 minutes to 1 hour.
The implanted device is programmed by a clinician in an outpatient setting using a portable tablet.
Meindert Boysen, director of the centre for health technology evaluation at NICE, said: "Clinical trial evidence seen by our independent committee shows that Axonics can help improve quality of life for people with symptoms caused by an overactive bladder.
"This device will last longer than the current non-rechargeable system, resulting in a cost saving for the NHS after six years of use, and, importantly for patients, fewer replacement surgeries."
It is estimated around 19 per cent of people in the UK have an overactive bladder – symptoms may include needing to pass urine frequently with or without an uncontrollable urge. Women and the elderly are groups most affected. Leakage of urine associated with the strong desire to go to the toilet may also be a problem.
Health Minister Nicola Blackwood said: "This revolutionary device offers a new solution to help people managing this condition to go about their everyday lives free from worry or disruption.
"Our priority is to ensure NHS patients have access to the latest innovative treatments and today's announcement is further proof that the UK continues to be the world-leading destination for revolutionary healthcare."
The Axonics device would be an option for people with symptoms of overactive bladder who have not responded to conservative treatments or drug therapy, in line with NICE guidelines NG123 and CG97.
Each Axonics device costs £9,660. Based on current data it is thought the battery will last for around six years before it needs replacing although there is some evidence to suggest it could last as long as 15 years. Cost modelling by NICE suggests that six years is the point at which the device becomes cost saving compared with the current non-rechargeable system. Axonics SNS has potential to save the NHS around £6,200 per patient assuming a 15-year life span. Cost savings are mainly driven by the increased length of time before a replacement system is needed.
A consultation on the draft medical technology guidance is open to stakeholders via nice.org.uk until Friday 13 March 2020.
Read the draft guidance and take part in the consultation
Channel website: https://www.nice.org.uk/
Original article link: https://www.nice.org.uk/news/article/wireless-device-recommended-for-treating-people-with-overactive-bladder
NICE is gearing up for the evaluation of further digital health technologies as pilot project produces first result
Blog posted by: Meindert Boysen, director of NICE's centre for health technology evaluation, 08 January 2021.
Treatment for men with enlarged prostate is recommended by NICE for NHS adoption
Final guidance from NICE recommends the PLASMA system.
NICE collaboration on streamlined licensing and patient access process for new medicines opened on January 1st
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland
Shared decision making is an integral part of healthcare, says NICE
Shared decision making between patients and clinicians should be embedded throughout healthcare services, says NICE, in draft guidance published yesterday.
NICE, RCGP and SIGN publish guideline on managing the long-term effects of COVID-19
NICE, the Royal College of General Practitioners (RCGP) and the Scottish Intercollegiate Guidelines Network (SIGN) have today (18 December 2020) published a guideline on the management of the long-term effects of COVID-19 (also known as Long COVID)
NICE, PHE and SACN publish rapid COVID-19 guidance on vitamin D
NICE, PHE and SACN yesterday published rapid guidance on vitamin D for COVID-19
New LSE master's degree in Evaluation of Health Care Interventions and Outcomes
NICE is collaborating with the London School of Economics and Political Science (LSE) to develop an executive master's degree in health care decision-making.
NICE and NIHR: working together to produce research with impact
Alice and Zoe discuss how the National Institute of Health Research (NIHR) and NICE work in partnership and identify key research priorities from NICE guidance.
Shared Learning Awards 2020: Winner announced
Virtual ceremony sees a project from Avon and Wiltshire Mental Health Partnership Trust voted winning submission.